Thrombotargets key strategic goal is to continue to enhance and develop our product pipeline as well as out-license our HTS platforms. This strategy provides to the partners powerful drug candidates and it strengthens our position as a leading biotech company in Thrombosis and Hemostasia areas.

Thrombotargets (www.thrombotargets.com) is a privately held group of Biotech companies focused on the discovery and development of innovative drugs in Haemostasis, Thrombosis and Atherosclerosis. Thrombotargets Corporation (N. Carolina, USA) is responsible for Drug Development and High Throughput Screening; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead validation and Lead optimization and Biotech Libraries for engineered targeted libraries.

Thrombotargets group is creating a continuously growing and innovative pipeline.

Presently, two of most innovative drug candidates, TT-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel anticoagulant monoclonal antibody in pre clinical phase. Thrombotargets will start Phase I trial with TT-103 in Q1 2008, and has received the Orphan Drug Designation to the FDA for TT-103 MH in February 2007. TT-111 and TT-112 are two innovative antifibrinolytic compounds, having higher potency than current commercialised antifibrinolytic drugs, which are being developed in collaboration with Asinex, Russia.